SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 3 filers reported holding SAGE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,984 | -76.4% | 582,272 | -46.1% | 0.00% | -71.4% |
| Q2 2023 | $50,789 | -36.6% | 1,080,153 | -43.4% | 0.01% | -41.7% |
| Q1 2023 | $80,077 | +10.7% | 1,908,391 | +0.6% | 0.01% | 0.0% |
| Q4 2022 | $72,364 | -99.9% | 1,897,322 | -11.4% | 0.01% | -14.3% |
| Q3 2022 | $83,819,000 | +24.9% | 2,140,411 | +3.0% | 0.01% | +75.0% |
| Q2 2022 | $67,104,000 | -6.1% | 2,077,534 | -3.8% | 0.01% | +14.3% |
| Q1 2022 | $71,446,000 | +18.6% | 2,158,504 | +52.4% | 0.01% | +40.0% |
| Q4 2021 | $60,259,000 | -3.3% | 1,416,522 | +0.7% | 0.01% | -16.7% |
| Q3 2021 | $62,339,000 | -30.2% | 1,406,889 | -10.5% | 0.01% | -25.0% |
| Q2 2021 | $89,280,000 | -50.4% | 1,571,553 | -34.7% | 0.01% | -55.6% |
| Q1 2021 | $180,152,000 | -11.7% | 2,406,847 | +2.1% | 0.02% | -14.3% |
| Q4 2020 | $203,934,000 | +30.4% | 2,357,342 | -7.9% | 0.02% | +16.7% |
| Q3 2020 | $156,408,000 | +33.4% | 2,559,034 | -9.2% | 0.02% | +20.0% |
| Q2 2020 | $117,216,000 | +37.7% | 2,819,052 | -4.9% | 0.02% | +15.4% |
| Q1 2020 | $85,135,000 | -79.1% | 2,964,308 | -47.5% | 0.01% | -75.5% |
| Q4 2019 | $407,815,000 | -61.1% | 5,649,188 | -24.3% | 0.05% | -64.2% |
| Q3 2019 | $1,047,048,000 | -27.6% | 7,463,451 | -5.6% | 0.15% | -27.1% |
| Q2 2019 | $1,447,195,000 | +9.4% | 7,904,284 | -4.9% | 0.20% | +4.6% |
| Q1 2019 | $1,322,296,000 | +72.1% | 8,313,715 | +3.7% | 0.19% | +49.2% |
| Q4 2018 | $768,275,000 | -29.8% | 8,020,411 | +3.5% | 0.13% | -18.8% |
| Q3 2018 | $1,095,060,000 | -8.3% | 7,752,634 | +1.6% | 0.16% | -12.6% |
| Q2 2018 | $1,194,704,000 | +3.6% | 7,632,429 | +6.7% | 0.18% | 0.0% |
| Q1 2018 | $1,152,637,000 | +10.9% | 7,156,124 | +13.4% | 0.18% | +8.3% |
| Q4 2017 | $1,039,537,000 | +257.5% | 6,311,317 | +35.2% | 0.17% | +238.0% |
| Q3 2017 | $290,776,000 | +3.2% | 4,667,359 | +31.9% | 0.05% | -2.0% |
| Q2 2017 | $281,836,000 | +19.0% | 3,538,873 | +6.2% | 0.05% | +15.9% |
| Q1 2017 | $236,890,000 | +81.3% | 3,333,190 | +30.3% | 0.04% | +69.2% |
| Q4 2016 | $130,628,000 | +102.4% | 2,558,333 | +82.5% | 0.03% | +100.0% |
| Q3 2016 | $64,547,000 | +354.8% | 1,401,678 | +197.6% | 0.01% | +333.3% |
| Q2 2016 | $14,193,000 | +16.0% | 471,070 | +23.5% | 0.00% | 0.0% |
| Q1 2016 | $12,232,000 | -45.0% | 381,525 | 0.0% | 0.00% | -40.0% |
| Q4 2015 | $22,243,000 | -28.2% | 381,525 | -47.8% | 0.01% | -28.6% |
| Q3 2015 | $30,958,000 | +1.5% | 731,510 | +75.0% | 0.01% | +16.7% |
| Q2 2015 | $30,509,000 | +575.7% | 417,927 | +365.0% | 0.01% | +500.0% |
| Q1 2015 | $4,515,000 | – | 89,878 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |